Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares stood at 2.47 million during the last session, with the company’s beta value hitting 1.93. At the close of trading, the stock’s price was $2.38, to imply a decrease of -7.03% or -$0.18 in intraday trading. The FATE share’s 52-week high remains $8.83, putting it -271.01% down since that peak but still an impressive 17.65% since price per share fell to its 52-week low of $1.96. The company has a valuation of $271.07M, with an average of 4.26 million shares in intraday trading volume over the past 10 days and average of 2.13 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Fate Therapeutics Inc (FATE), translating to a mean rating of 2.53. Of 8 analyst(s) looking at the stock, 1 analyst(s) give FATE a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.43.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fate Therapeutics Inc (NASDAQ:FATE) trade information
After registering a -7.03% downside in the last session, Fate Therapeutics Inc (FATE) has traded red over the past five days. The 5-day price performance for the stock is -24.92%, and -11.19% over 30 days. With these gigs, the year-to-date price performance is -36.36%. Short interest in Fate Therapeutics Inc (NASDAQ:FATE) saw shorts transact 10.39 million shares and set a 7.2 days time to cover.
The extremes give us $5 and $6 for target low and target high price respectively. As such, FATE has been trading -152.1% off suggested target high and -110.08% from its likely low.
Fate Therapeutics Inc (FATE) estimates and forecasts
Looking at statistics comparing Fate Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Fate Therapeutics Inc (FATE) shares are -37.37% down over the last 6 months, with its year-to-date growth rate lower than industry average at -4.88% against 17.40%. The rating firms project that company’s revenue will shrink -78.52% compared to the previous financial year.
Revenue forecast for the current quarter as set by 13 analysts is 1.57M. Meanwhile, for the current quarter, a total of 10 analyst(s) estimate revenue growth to 1.2M.Earnings reports from the last fiscal year show that sales brought in 1.68M and 1.93M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -6.49% before dropping -37.80% in the following quarter.
FATE Dividends
Fate Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Fate Therapeutics Inc insiders hold 2.17% of total outstanding shares, with institutional holders owning 102.69% of the shares at 104.97% float percentage. In total, 102.69% institutions holds shares in the company, led by REDMILE GROUP, LLC. As of 2024-06-30, the company held over 13.17 million shares (or 13.0252% of shares), all amounting to roughly $43.19 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 10.57 million shares, or about 10.4544% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $34.67 million.
